Veldic, Marin
Millischer, Vincent http://orcid.org/0000-0003-1919-9649
Port, John D. http://orcid.org/0000-0002-4237-7776
Ho, Ada Man-Choi http://orcid.org/0000-0003-4989-8782
Jia, Yun-Fang
Geske, Jennifer R.
Biernacka, Joanna M. http://orcid.org/0000-0001-9350-4440
Backlund, Lena http://orcid.org/0000-0001-9399-5024
McElroy, Susan L.
Bond, David J.
Villaescusa, J. Carlos http://orcid.org/0000-0001-9456-9828
Skime, Michelle
Choi, Doo-Sup
Lavebratt, Catharina http://orcid.org/0000-0003-4987-2718
Schalling, Martin
Frye, Mark A.
Article History
Received: 7 December 2018
Revised: 7 March 2019
Accepted: 10 April 2019
First Online: 23 May 2019
Competing interests
: This work was supported by the National Institute of Mental Health RO1MH079261, National Alliance for Research in Depression and Schizophrenia (NARSAD) Independent Investigator Award, the Marriott Foundation and Mayo Clinic Genomics of Addition to Dr. Frye, and by the Mayo Foundation for Medical Education and Research as well as the J. Willard and Alice S. Marriott Foundation grant to Dr. Veldic. The project was supported by grants from the Karolinska Institutet, the KI-Mayo Collaboration (MV, CL, VM), the Swedish Research Council (2016-02653 (MS); 2014-10171 (CL)), the Swedish Brain Foundation (FO2017-0129 (CL); FO2018-0141 (CL)) and grants from the regional agreement on medical training and clinical research (ALF) between the Stockholm County Council and the Karolinska Institutet (SLL20170292 (CL)). Dr. Choi is a scientific advisory board member to Peptron Inc. Dr. Frye is a consultant (for Mayo Clinic) to Janssen, Mitsubishi Tanabe Pharma Corporation, Myriad, Sunovion, and Teva Pharmaceuticals. None of this funding contributed to work carried out in this study.